In fact, Crohn's disease patients are 5–10 times more likely to receive anti-tumor necrosis factor-α (TNF-α) treatment than ulcerative colitis patients, which could be a key influencing factor leading to differing results between previous studies and our findings (44, 45). Here, TNF is linked to Crohn disease.